Korean Journal of Veterinary Research (대한수의학회지)

The Korean Society of Veterinary Science (대한수의학회)
권호 표지
DOI QR코드

DOI QR Code

The protective effects of sonicated Bordetella bronchiseptica bacterin on the immunosuppression of spleen cells induced by anti-cancer drugs (5-fluorouracil, doxorubicin, and vincristine)

항암제 (5-fluorouracil, doxorubicin, vincristine)로 인한 비장세포의 면역억제에 대한 Bordetella bronchiseptica의 보호 효과

  • Lee, You-Jeong (Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University) ;
  • Joo, Hong-Gu (Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University)
  • 이유정 (제주대학교 수의과대학 수의약리학실) ;
  • 주홍구 (제주대학교 수의과대학 수의약리학실)
  • Received : 2022.05.16
  • Accepted : 2022.06.24
  • Published : 2022.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

5-Fluorouracil, doxorubicin, and vincristine are chemotherapy agents used to treat various cancers, such as breast cancer and lymphoma for decades, and their effects on cancer have been proven. On the other hand, these anti-cancer drugs cause fatal side effects, including immunosuppression. This study investigated whether sonicated Bordetella bronchiseptica bacterin (B. bronchiseptica) can attenuate the immunosuppression of spleen cells induced by these chemotherapy agents and which subsets of spleen cells were affected. B. bronchiseptica increased the metabolic activity of spleen cells treated with 3 anti-cancer drugs. Cell death analysis using Annexin V/propidium iodide showed that B. bronchiseptica markedly decreased the death of spleen cells. The subsets of spleen cells were analyzed by flow cytometry using a surface marker-specific antibody. B. bronchiseptica increased nitric oxide production in the spleen cells treated with anti-cancer drugs (p < 0.0001). Despite the pharmacological effects of anti-cancer drugs, many patients suffer from the fatal side effects of immunosuppression. This study provides valuable information on how to overcome chemotherapy-induced immunosuppression.

Keywords

Acknowledgement

이 성과는 정부(과학기술정보통신부)의 재원으로 한국연구재단의 지원(No. NRF-2020R1F1A1069946)에 의해 수행되었으며, 이에 감사드립니다.

References

  1. Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother 2021; 137:111285. https://doi.org/10.1016/j.biopha.2021.111285
  2. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009;16:3267-3285. https://doi.org/10.2174/092986709788803312
  3. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9:790-803. https://doi.org/10.1038/nrd3253
  4. Lewis WD, Lilly S, Jones KL. Lymphoma: diagnosis and treatment. Am Fam Physician 2020;101:34-41.
  5. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer Res 2009;69:5383-5391. https://doi.org/10.1158/0008-5472.CAN-08-3845
  6. Gupta S, Goyal P, Mattana J. Bordetella bronchiseptica pneumonia a thread in the diagnosis of human immunodeficiency virus infection. IDCases 2019;15:e00509. https://doi.org/10.1016/j.idcr.2019.e00509
  7. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Harris DE, Holden MT, Churcher CM, Bentley SD, Mungall KL, Cerdeno-Tarraga AM, Temple L, James K, Harris B, Quail MA, Achtman M, Atkin R, Baker S, Basham D, Bason N, Cherevach I, Chillingworth T, Collins M, Cronin A, Davis P, Doggett J, Feltwell T, Goble A, Hamlin N, Hauser H, Holroyd S, Jagels K, Leather S, Moule S, Norberczak H, O'Neil S, Ormond D, Price C, Rabbinowitsch E, Rutter S, Sanders M, Saunders D, Seeger K, Sharp S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Unwin L, Whitehead S, Barrell BG, Maskell DJ. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 2003;35:32-40.
  8. Dunne A, Mielke LA, Allen AC, Sutton CE, Higgs R, Cunningham CC, Higgins SC, Mills KH. A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine. Mucosal Immunol 2015;8:607-617. https://doi.org/10.1038/mi.2014.93
  9. Gueirard P, Minoprio P, Guiso N. Intranasal inoculation of Bordetella bronchiseptica in mice induces long-lasting antibody and T-cell mediated immune responses. Scand J Immunol 1996;43:181-192. https://doi.org/10.1046/j.1365-3083.1996.d01-30.x
  10. Yim SH, Hahn TW, Joo HG. Bordetella bronchiseptica antigen enhances the production of Mycoplasma hyopneumoniae antigen-specific immunoglobulin G in mice. J Vet Sci 2017;18: 327-332. https://doi.org/10.4142/jvs.2017.18.3.327
  11. Lee YJ, Han Y, Joo HG. Bordetella bronchiseptica is a potent and safe adjuvant that enhances the antigen-presenting capability of dendritic cells. Korean J Physiol Pharmacol 2020;24: 47-52. https://doi.org/10.4196/kjpp.2020.24.1.47
  12. Kim HJ, Joo HG. Paclitaxel inhibits the hyper-activation of spleen cells by lipopolysaccharide and induces cell death. J Vet Sci 2016;17:453-458. https://doi.org/10.4142/jvs.2016.17.4.453
  13. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008;26:453-479. https://doi.org/10.1146/annurev.immunol.26.021607.090357
  14. Noben-Trauth N, Hu-Li J, Paul WE. Conventional, naive CD4+ T cells provide an initial source of IL-4 during Th2 differentiation. J Immunol 2000;165:3620-3625. https://doi.org/10.4049/jimmunol.165.7.3620
  15. Riou C, Dumont AR, Yassine-Diab B, Haddad EK, Sekaly RP. IL-4 influences the differentiation and the susceptibility to activation-induced cell death of human naive CD8+ T cells. Int Immunol 2006;18:827-835. https://doi.org/10.1093/intimm/dxl019
  16. Kelly E, Won A, Refaeli Y, Van Parijs L. IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol 2002;168:597-603. https://doi.org/10.4049/jimmunol.168.2.597
  17. Ropke C, Gladstone P, Nielsen M, Borregaard N, Ledbetter JA, Svejgaard A, Odum N. Apoptosis following interleukin-2 withdrawal from T cells: evidence for a regulatory role of CD18 (beta 2-integrin) molecules. Tissue Antigens 1996;48: 127-135. https://doi.org/10.1111/j.1399-0039.1996.tb02617.x